What is Revvity's diagnostics — foreign currency translation?

Revvity (RVTY) reported diagnostics — foreign currency translation of -$9.83M in Q1 2026.

How has Revvity's diagnostics — foreign currency translation changed year-over-year?

Revvity's diagnostics — foreign currency translation decreased by 169.0% year-over-year, from $14.24M to -$9.83M.

What does diagnostics — foreign currency translation mean?

This metric represents the net impact of fluctuations in exchange rates on the financial results of the diagnostics business segment. It reflects the gains or losses recognized when translating the financial statements of foreign subsidiaries into the reporting currency.

Revvity (RVTY) Diagnostics — Foreign currency translation

Screener

Other segment segments

Life Sciences

-$24.95M-174%

Similar metrics at other companies

COHRIndustrial — Foreign currency translation

-$59.86M—

SUNBSpecialty — Foreign currency translation

$1M+500%

THOOther — Foreign currency translation

$0—

ABMAviation — Foreign currency translation

$25K-75.0%

ABMEducation — Foreign currency translation

$0—

EFXInternational — Foreign currency translation

$3.7M-94.3%

Other financials

Income statement

See full

Revenue$711.1M+7.0%

Gross profit$387.7M+3.2%

Operating income$75.9M+5.1%

Net income$40.7M-3.6%

EPS (diluted)$0.36+2.9%

Balance sheet

See full

Cash & equivalents$861.5M-24.3%

Total debt$3.9B+17.8%

Total equity$7.2B-5.9%

Total assets$12.0B-2.9%

Cash flow

See full

Operating cash flow$115.2M-10.1%

CapEx$19.8M+23.7%

Free cash flow$95.5M-14.9%

Valuation

See full

Market cap$12.83B+28.7%

Enterprise value$15.91B+28.6%

P/E53.5×+18.6×

P/S4.4×+0.9×

Profitability

See full

Gross margin48.5%—

Operating margin12.4%-1.1pp

Net margin8.3%-2.1pp

FCF margin17%-1.9pp

Returns & leverage

See full

Return on equity3.2%-0.5pp

Debt / equity0.5×+0.1×

Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.

The source filing: Revvity’s 10-Q, filed May 12, 2026.

Filed: May 12, 2026, 4:07 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0000031791-26-000019

Line item	Life Sciences	Diagnostics	Consolidated
Balance at December 28, 2025	$4,744,962	$1,868,531	$6,613,493
Foreign currency translation	(24,952)	(9,826)	(34,778)
Acquisitions	32,035	—	32,035
Balance at April 5, 2026	$4,752,045	$1,858,705	$6,610,750

Item 1.Unaudited Financial Statements

FAQ

What is Revvity's diagnostics — foreign currency translation?: Revvity (RVTY) reported diagnostics — foreign currency translation of -$9.83M in Q1 2026.
How has Revvity's diagnostics — foreign currency translation changed year-over-year?: Revvity's diagnostics — foreign currency translation decreased by 169.0% year-over-year, from $14.24M to -$9.83M.
What does diagnostics — foreign currency translation mean?: This metric represents the net impact of fluctuations in exchange rates on the financial results of the diagnostics business segment. It reflects the gains or losses recognized when translating the financial statements of foreign subsidiaries into the reporting currency.